BRIEF-Merck KGaA says IIIb study of Kuvan reached primary endpoint

FRANKFURT, April 24 Thu Apr 24, 2014 2:21am EDT

Related Topics

FRANKFURT, April 24 (Reuters) - Merck KGaA : * Announces positive outcome of iiib study for kuvan * Says positive outcome of study will enable submission of regulatory

application for a label extension later this year

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.